ANI Pharmaceuticals announced the availability of Propafenone HCl Tablets, the generic version of GlaxoSmithKline‘s Rythmol.
RELATED: Antiarrhythmic Drug Now Available in Oral Solution Formulation
Rythmol is a Class IC antiarrhythmic indicated for documented life-threatening sustained ventricular arrhythmias, and to prolong recurrence of disabling paroxysmal atrial fibrillation/flutter or paroxysmal supraventricular tachycardia in patients without structural heart disease. It has local anesthetic effects and a direct stabilizing action on myocardial membranes. In Purkinje fibers, and to a lesser extent myocardial fibers, propafenone reduces the fast inward current carried by sodium ions. Diastolic excitability threshold is increased and effective refractory period prolonged. Propafenone reduces spontaneous automaticity and depresses triggered activity.
Propafenone HCl Tablets are available in 150mg, 225mg, and 300mg strengths.
For more information visit ANIPharmaceuticals.com.